Alliance with Sirius Analytical
June 21 2012 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
21 June 2012
Cyprotex PLC
Cyprotex strengthen physicochemical profiling services in
alliance with Sirius Analytical
21 June, 2012 - Cyprotex PLC (AIM:CRX), the preclinical ADME-Tox
services company, and Sirius Analytical Instruments Ltd, leaders in
physiochemical profiling, today announce that they have signed a
strategic alliance which will allow Cyprotex to offer Sirius
Analytical's physicochemical property services to their
customers.
The physicochemical properties of a drug can influence its
absorption and distribution into tissues, as well as the drug's
binding characteristics. During the drug discovery process, many
prediction technologies heavily rely on measuring certain physical
properties of compounds of interest, in particular lipophilicity,
pKa and solubility, as they are critical to the drug's efficacy
(activity) and toxicology profile.
Sirius Analytical's instrumentation is the most reliable and
advanced in the market and is routinely used within the industry
for physicochemical property determination. The most recent
introduction, the SiriusT3, is a fully automated system for rapid
and accurate measurement of physicochemical properties using small,
often sub-milligram, quantities of material.
Dr. Anthony Baxter, Cyprotex's Chief Executive Officer,
commented: "Physicochemical property determination is key to our
understanding of how a drug behaves in the body. The properties are
used routinely in prediction methods and feature in our PBPK
modelling software, Cloe(R) PK. Sirius have an impressive record of
over 20 years expertise in this specialist field. By partnering
with Sirius, Cyprotex customers will have access to a broader range
of expert services which complement our existing portfolio of
ADME-Tox services."
Brett Hughes, Chief Executive Officer of Sirius Analytical,
added: "We are delighted to begin this strategic partnership with
Cyprotex. In the highly competitive contract research space,
Cyprotex are renowned for their fast, accurate and professional
service, making them an obvious choice of partner for Sirius
Analytical. We are looking forward to making our popular PhysChem
services even more widely available through our exposure to
Cyprotex's large and growing client portfolio."
For further information:
Cyprotex PLC Tel: +44 (0) 1625 505
100
Dr Anthony Baxter, Chief Executive Officer ir@cyprotex.com
John Dootson, Chief Financial Officer www.cyprotex.com
Mark Warburton, Chief Operating Officer and
Legal Counsel
Sirius Analytical Instruments Limited Tel: +44 (0) 1342 820
720
Brett Hughes, Chief Executive Officer info@sirius-analytical.com
www.sirius-analytical.com
Singer Capital Markets Limited (broker to Cyprotex) Tel: +44 (0) 20 3205
7500
Shaun Dobson shaun.dobson@singercm.com
Claes Spang claes.spang@singercm.com
www.singercm.com
FTI Consulting Tel: +44 (0) 20 7831
3113
Ben Brewerton cyprotex@fticonsulting.com
Simon Conway www.fticonsulting.com
Mo Noonan
Notes to Editors
About Sirius Analytical Instruments Limited
Established in 1989, Sirius Analytical specialises in the
provision of physicochemical instruments, data and consultancy
services with facilities in the US and UK. Sirius Analytical
specialise in designing and manufacturing unique analytical
instrumentation for the pharmaceutical industry. Sirius instruments
provide accurate and reliable values for pKa, logP, logD,
solubility and dissolution, using methods based on highly automated
potentiometric and spectroscopic titration. The ability of New
Chemical Entities to cross biological membranes such as the
gastro-intestinal tract, blood-brain barrier, skin and cell walls
in general, depends on these critical physicochemical parameters.
Sirius also offer an analytical service for high quality PhysChem
outsourcing, used by hundreds of clients worldwide.
About Cyprotex PLC
Cyprotex is based in Macclesfield, near Manchester in the UK,
and Watertown, Boston in the US and is listed on the AIM market of
the London Stock Exchange (CRX). The company was established in
1999 and works with more than 700 partners ranging from small
biotechs to large pharma companies. Cyprotex acquired Apredica and
the assets of Cellumen Inc. in August 2010 and the combined
business provides support for a wide range of experimental and
computational ADME-Tox and PK services, extending from early drug
discovery through to IND submission. The company's core
capabilities include high quality in vitro ADME screening services,
mechanistic toxicology and high content toxicology screening
services and predictive modelling using PBPK and QSAR techniques,
including Cloe(R) PK for in vivo PK prediction. For more
information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASELFWSFESELM
Cyprotex (LSE:CRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From Sep 2023 to Sep 2024